Company Overview and News

0
Cynata Reports Positive 28-day Data From Cohort B of Phase 1 Trial of CYP-001 in GvHD

2018-06-21 globenewswire
MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD).
CYP CYYNF

0
Cynata Reports Positive Six-Month Data from Cohort A in Phase 1 Trial of CYP-001 in GvHD

2018-06-12 globenewswire
MELBOURNE, Australia, June 12, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and sustained overall survival rates from a six month follow-up assessment of patients enrolled in Cohort A of its Phase 1 clinical trial of CYP-001, the company’s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD).
CYP CYYNF

0
$5.2m placement of shares to Fidelity International

2018-05-30 globenewswire
MELBOURNE, Australia, May 30, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) (‘Cynata’) is pleased to announce a A$5.2 million share placement to Fidelity International (‘Fidelity’). Upon completion of the placement, together with their existing equity position, Fidelity’s holding in Cynata will increase to approximately 10.0%.
CYP CYYNF

0
Cynata Therapeutics treats final patient in stem cell clinical trial

2018-05-25 proactiveinvestors.com.au
Cynata Therapeutics Ltd (ASX:CYP) has treated the final patient in its phase I clinical trial of CYP-001 for adults with steroid-resistant acute graft-versus-host-disease (GvHD).
CYP CYYNF

0
Cynata Therapeutics Completes Patent Application to Cover Cymerus™ Stem Cell Technology in the Treatment of Side Effects Related to CAR-T Therapy

2018-04-20 globenewswire
MELBOURNE, Australia, April 20, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), today announced that it has completed the filing of a patent application with IP Australia that would cover the therapeutic use of its Cymerus™ stem cell technology in the treatment of adverse reactions associated with chimeric antigen receptor T-cell (CAR-T) immunotherapy.
CYP CYYNF

0
Cynata Therapeutics granted another patent for its unique stem cell technology

2018-04-11 proactiveinvestors.com.au
Cynata Therapeutics Ltd (ASX:CYP) has been granted a further patent covering aspects of its proprietary Cymerus™ stem cell platform by the U.S. Patent and Trademark Office (USPTO).
CYP CYYNF

0
FDA Grants Orphan Drug Designation to Cynata’s Lead Cymerus™ MSC Product, CYP-001

2018-03-28 globenewswire
MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the United States Food and Drug Administration (FDA) has granted Cynata Orphan Drug Designation for CYP-001 for the treatment of acute graft versus host disease (GvHD). CYP-001 is the lead mesenchymal stem cell (MSC) product manufactured using Cynata’s proprietary Cymerus platform manufacturing technology.
CYP CYYNF

0
Amzalak closes in on leader Ellis as Jatenergy goes gangbusters

2018-03-23 smh.com.au
Mendy Amzalak of AMZ Capital has narrowed the gap with race leader Angie Ellis of 80 20 Investments, in week three of the four-week shares race.
GLL ORNGF CYYNF CYP ORNQF OGX

0
Ellis maintains lead as Smart Park fires up

2018-03-17 smh.com.au
Angie Ellis of 80 20 Investments has maintained her lead over her closest rival, Mendy Amzalak of AMZ Capital, in week two of the four-week shares race with her original $100,000 portfolio worth $114,584.
GLL ORNGF CYYNF CYP ORNQF OGX

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...